Keynote Address Tackles AI’s Role in Health Care, Eye Care - AJMC
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care. “We are embarking on what is the greatest experiment in the history of medicine in trying to get this right,” Robert M. Wachter, MD, began his keynote address for the American Academy of Ophthalmology 2026 Annual Meeting on October 10, 2026. For Wachter, artificial intelligence (AI) represents a promising path forward for health care that should be encouraged. AI Can Provide Scalable Specialty Expertise in Health CareWachter emphasized that informed optimism is the way to approach AI in the future as the tools become more normal rather than novel. According to an NBC News poll, public sentiment toward AI in health care specifically is mostly positive, with 47% claiming that it would bring more good than harm compared with 30% who thought it would bring more harm than good.1 This could allow for more ease in introducing AI into health care than in other areas, as the pushback is not as strong in this area, said Wachter.
This article is an excerpt. To read the full content, visit the original source. AJMC
Related articles
Bioengineer.org | Switching HIV drugs or adding zoledronic acid rebuilds bone lost to tenofovir - European AIDS Treatment Group
Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.
A New Injection Makes Fat Cells Self-Destruct, And Might Prevent GLP-1 Weight Regain - ScienceAlert
The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.
0 comments
No comments yet. Be the first to share your thoughts!